prostate cancer – Medxy AI

Specialist Cardiovascular Referral Enhances Cholesterol Management in Prostate Cancer Patients: Insights from a Global Randomized Trial

By MedXY 09/01/2026

A randomized clinical trial demonstrates that routine cardiovascular specialist referral for prostate cancer patients improves cholesterol control but does not reduce major cardiovascular events over nearly 6 years.

Diabetes & Endocrinology news Oncology

Metabolic Dysfunction Following Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer: Clinical Implications and Risks

By MedXY 08/15/2026

This study reveals a significant early onset of metabolic syndrome in men with prostate cancer treated with combined ADT and ARPI therapies, highlighting the necessity for multidisciplinary metabolic monitoring and interventions.

news Oncology Urology

Predictive Mathematical Biomarkers Transform Personalized Adaptive Therapy in Prostate Cancer

By MedXY 08/08/2026

Mathematical biomarkers derived from initial PSA dynamics effectively predict adaptive therapy outcomes in prostate cancer, enabling personalized treatment strategies that outperform traditional PSA measures.

news Radiology Urology

Enhanced Detection of Clinically Significant Prostate Cancer: Insights from the Stockholm3-MRI Screening Study Two-Year Follow-up

By MedXY 06/25/2026

The Stockholm3 test combined with MRI screening significantly improves detection of clinically significant prostate cancer compared to PSA alone, reducing missed cases and unnecessary biopsies in a population-based study with 2-year follow-up.

Cardiology news Oncology

GnRH Antagonists May Spare the Heart: Evidence of Reduced Coronary Plaque Progression in Prostate Cancer Patients

By MedXY 03/09/2026

A randomized clinical trial indicates that the GnRH agonist leuprolide significantly accelerates coronary plaque progression compared to the antagonist relugolix in men with prostate cancer, suggesting a potential biological mechanism for differential cardiovascular risk between ADT classes.

news Oncology Urology

Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy

By MedXY 03/06/2026

A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standards for recurrent prostate cancer.

Clinical Updates news Oncology Radiology Urology

Risk Stratification in PSMA PET-Staged Oligorecurrent Prostate Cancer: Clinical Synthesis of the PORTAL Nomogram and Metastasis-Directed Therapy

By MedXY 02/26/2026

This review analyzes the PORTAL study’s nomogram for predicting ADT-free survival in oligorecurrent prostate cancer, synthesizing evidence on PSMA PET-guided SBRT and the clinical utility of risk-based patient selection.

news Oncology Urology

Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity

By MedXY 02/20/2026

A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications for patients with localized radiorecurrent prostate cancer.

Cardiology news Oncology

GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients

By MedXY 02/19/2026

A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offering a potential biological explanation for differential cardiovascular risks.

news Oncology Urology

Metastasis-Directed Therapy Delivers Clear Progression Benefits in Oligometastatic Prostate Cancer: The WOLVERINE IPD Meta-Analysis

By MedXY 02/18/2026

The WOLVERINE individual patient data meta-analysis confirms that metastasis-directed therapy significantly improves progression-free and castration resistance-free survival in oligometastatic prostate cancer, providing high-level evidence for a paradigm shift in clinical management.

news Oncology Urology

Low Baseline PSA Predicts Exceptional Long-Term Safety: A 20-Year Paradigm Shift in Prostate Cancer Screening

By MedXY 02/09/2026

A 20-year cohort study shows that baseline PSA levels in men aged 45-70 are highly predictive of long-term prostate cancer risk, with PSA <1.0 ng/mL indicating a very low 20-year incidence of 3.3%, supporting extended screening intervals for low-risk individuals.

Clinical Updates news Oncology

Prostate Cancer Statistics 2025: The Resurgence of Advanced Disease and Persistent Racial Disparities

By MedXY 01/14/2026

This review analyzes 2025 prostate cancer data, highlighting a 3% annual incidence increase primarily driven by advanced-stage disease. It explores age-specific trends, significant racial inequities in mortality, and the clinical challenges of optimizing early detection while managing advanced disease complications.

news Oncology Urology

Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial

By MedXY 01/13/2026

The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.

news Radiology Urology

Shifting the Paradigm: Noncontrast MRI-First Screening Strategy Significantly Increases Detection of Clinically Significant Prostate Cancer

By MedXY 01/10/2026

The PROSA trial reveals that a contrast-free biparametric MRI-first screening approach doubles the detection of clinically significant prostate cancer compared to PSA-triggered pathways, while maintaining favorable cost-effectiveness and benefit-harm ratios.

news Oncology Urology

Molecular Imaging and PET-Guided Dose Escalation Revolutionize Salvage Radiotherapy: Insights from EMPIRE-1 and EMPIRE-2

By MedXY 01/10/2026

The EMPIRE trials demonstrate that integrating molecular imaging and PET-guided dose escalation significantly improves event-free survival in patients requiring salvage radiotherapy for prostate cancer recurrence.

AI news Oncology Urology

Multimodal AI Outperforms Clinical Nomograms in Predicting Metastasis for Post-Prostatectomy Biochemical Recurrence

By MedXY 01/10/2026

A validated multimodal AI model using digital pathology and clinical data significantly improves risk stratification for prostate cancer patients with biochemical recurrence, identifying those who derive the greatest benefit from salvage hormone therapy.

news Oncology Urology

The NanoKnife Revolution: A Non-Thermal Leap Forward in Precision Prostate Cancer Care

By MedXY 01/10/2026

The PRESERVE trial demonstrates that Irreversible Electroporation (IRE) using the NanoKnife System is a safe and effective focal therapy for intermediate-risk prostate cancer, offering high success rates while preserving urinary and sexual health.

Clinical Updates news Oncology Urology

Stockholm3 Versus PSA in Prostate Cancer Screening: A Synthesis of 9-year Outcomes, Repeat Screening, and Multiethnic Validation

By MedXY 01/09/2026

This review synthesizes long-term outcomes and multiethnic data demonstrating that the Stockholm3 test significantly improves the detection of aggressive prostate cancer while reducing overdiagnosis and unnecessary procedures compared to traditional PSA-based screening.

news Oncology Urology

More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer

By MedXY 01/08/2026

Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while significantly increasing the risk of long-term gastrointestinal toxicity.

news Oncology Urology

Tailoring Systemic Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Evidence by Disease Volume and Timing of Metastasis

By MedXY 12/17/2025

A living network meta-analysis refines treatment strategies for mHSPC subgroups, favoring triplet therapy in synchronous high-volume cases and ARPI doublet therapy in others.